Crescendo Biologics, Ltd., a Cambridge, England, UK-based developer of multi-functional biologics with a focus on novel targeted T-cell engagers, completed a $70m (€57m) Series B financing.
The round was led by Andera Partners (formerly Edmond de Rothschild Investment Partners) with participation from Biodiscovery V, and joined by Quan Capital with its life sciences fund, Quan Venture Fund I, and existing investors Sofinnova Partners, IP Group, EMBL and Takeda Ventures.
Led by CEO Peter Pack, Crescendo Biologics is developing multi-functional Humabody® therapeutics in oncology. It is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships. To date, it has a collaboration with Takeda Pharma worth up to $790m.
The company intends to use the funds to advance the development of its lead programme, CB307, which stimulates local activation of tumour-specific T-cells, into the clinic and further expand its internal pipeline of products.